Literature DB >> 1810550

IMC bovine pericardial valve: 11 years.

D M Braile1, R V Ardito, O T Greco, A M Lorga.   

Abstract

From 1977 to 1988, 10,812 bovine pericardial valves were produced by IMC Biomédica and implanted. One thousand one hundred ninety-three were implanted by our group at IMC, including 666 exclusively in the mitral position. We are presenting our study of those mitral patients. Of the 663 patients, 586 were adults (over 21 years of age) and 77 were youngsters (under 21). Hospital mortality was 9.2%; 13.2% for the first 5.5 years (group 1) and 6.3% for the second 5.5 years (group II). Eleven year follow-up was 98.8% complete and the mean time was 3.8 years. The actuarial survival was 74.3% +/- 6.5% for the youngsters and 73.0% +/- 3.7% for the adults. The fatal valve-related late complications (death from thromboembolism, calcification, and endocarditis) had an incidence of 1% per patient-year as follows: (1) endocarditis, 0.6% per patient-year; (2) calcification 0.1% per patient-year; and (3) cerebral vascular accident, 0.3% per patient year. The actuarial study revealed 95.0% +/- 1.0% freedom from fatal complications related to the prosthesis. The nonfatal valve-related late complications had an incidence of 2.9% per patient-year as follows: (1) endocarditis, 0.5% per patient-year; (2) calcification, 1.8% per patient-year; (3) cerebral vascular accident, 0.3% per patient-year; (4) periprosthetic leakage, 0.2% per patient-year; and (5) rupture, 0.1% per patient-year.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1810550     DOI: 10.1111/jocs.1991.6.4s.580

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  4 in total

1.  A perspective on bovine pericardium for orbital implants.

Authors:  M S Bajaj; N Pushker
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

2.  Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Richard P Whitlock; Jack C Sun; Stephen E Fremes; Fraser D Rubens; Kevin H Teoh
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Late outcome analysis of the Braile Biomédica® pericardial valve in the aortic position.

Authors:  Lisandro Gonçalves Azeredo; Elinthon Tavares Veronese; José Augusto Duncan Santiago; Carlos Manuel de Almeida Brandão; Pablo Maria Alberto Pomerantzeff; Fabio Biscegli Jatene
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jul-Sep

Review 4.  Antithrombotic strategy in the three first months following bioprosthetic heart valve implantation.

Authors:  André R Durães; Milena A O Durães; Luis C L Correia; Roque Aras
Journal:  Arq Bras Cardiol       Date:  2013-10-08       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.